Ovarian Cancer Excellence Forum

Ovarian Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Podcasts

Part 1: Current Emerging Therapies for Platinum-Resistant Ovarian Malignancies

05/30/2022

In part 1 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses the current emerging therapies for platinum-resistant ovarian malignancies.

In part 1 of this 2-part podcast...

05/30/2022

Oncology

David O'Malley, MD, Ohio State University Comprehensive Cancer Center

Videos

Rucaparib Promising for BRCA–Positive Relapsed Ovarian Cancer: Results From the ARIEL4 Trial

07/04/2021

David O'Malley, MD, highlights promising results from a subgroup analysis of the effect of platinum sensitivity on the efficacy of rucaparib vs chemo for BRCA–positive, advanced, relapsed ovarian carcinoma.

David O'Malley, MD, highlights...

07/04/2021

Oncology

Videos

Richard Penson, MD, MRCP, Discusses Recent Advancements in the Treatment of Ovarian Cancer

07/01/2021

Dr Penson provides an overview of the latest evidence-based data regarding surgical and pharmacologic ovarian cancer treatment.

Dr Penson provides an overview...

07/01/2021

Oncology

Podcasts

ASNS Expression Predicts GLS1 Inhibitor Response in Ovarian Cancer

04/23/2021

Nakia Spencer, MSc, discusses the ongoing trial of asparagine synthetase (ASNS) expression to predict patient response to the GLS1 inhibitor IPN60090 in ovarian cancer.

Nakia Spencer, MSc, discusses...

04/23/2021

Oncology

Videos

Safety and Efficacy of Vaccination With Folate Receptor Alpha for Ovarian Cancer

04/01/2021

Roisin O'Cearbhaill, MD, discusses the safety and efficacy of TPIV200 vs GM-CSF alone in patients with high-grade, platinum-sensitive ovarian cancer.

Roisin O'Cearbhaill, MD,...

04/01/2021

Oncology

Podcasts

Niraparib as a Standard After First-Line Chemo for Advanced Ovarian Cancer

09/19/2020

Antonio Gonzalez-Martin, MD, discusses the PRIMA study of niraparib in patients with ovarian cancer.

Antonio Gonzalez-Martin, MD,...

09/19/2020

Oncology

Podcasts

Combo of RAF/MEK Inhibitor and Defactinib Shows Promise in Patients With KRAS+ Ovarian Cancer

09/14/2020

Udai Banerji, MD, discusses the findings and clinical significance of a phase 1 trial evaluating the use of VS-6766, a RAF/MEK inhibitor, plus defactinib in patients with KRAS-mutant ovarian cancer.

Udai Banerji, MD, discusses the...

09/14/2020

Oncology

Ovarian Cancer Excellence Forum

Specialties

Events

Year Round Education

HMP Global Products